Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
Kenneth H. Dinnon, Sarah R. Leist, Alexandra Schäfer, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 560-566
Open Access | Times Cited: 639

Showing 1-25 of 639 citing articles:

SARS-CoV-2 vaccines in development
Florian Krammer
Nature (2020) Vol. 586, Iss. 7830, pp. 516-527
Open Access | Times Cited: 2081
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 567-571
Open Access | Times Cited: 1441
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
Andrew G. Harrison, Lin Tao, Penghua Wang
Trends in Immunology (2020) Vol. 41, Iss. 12, pp. 1100-1115
Open Access | Times Cited: 1119
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1115
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Yixuan J. Hou, S. Chiba, Peter Halfmann, et al.
Science (2020) Vol. 370, Iss. 6523, pp. 1464-1468
Open Access | Times Cited: 960
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 3, pp. 477-488.e4
Open Access | Times Cited: 814
Animal models for COVID-19
César Muñoz‐Fontela, William E. Dowling, Simon G. P. Funnell, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 509-515
Open Access | Times Cited: 810
The evolution of SARS-CoV-2
Peter V. Markov, Mahan Ghafari, Martin Beer, et al.
Nature Reviews Microbiology (2023) Vol. 21, Iss. 6, pp. 361-379
Open Access | Times Cited: 797
SARS-CoV-2 pathogenesis
Mart M. Lamers, Bart L. Haagmans
Nature Reviews Microbiology (2022) Vol. 20, Iss. 5, pp. 270-284
Open Access | Times Cited: 712
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Peter Halfmann, Shun Iida, Kiyoko Iwatsuki‐Horimoto, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 687-692
Open Access | Times Cited: 603
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Sarah R. Leist, Kenneth H. Dinnon, Alexandra Schäfer, et al.
Cell (2020) Vol. 183, Iss. 4, pp. 1070-1085.e12
Open Access | Times Cited: 600
Innate immunity: the first line of defense against SARS-CoV-2
Michael Diamond, Thirumala‐Devi Kanneganti
Nature Immunology (2022) Vol. 23, Iss. 2, pp. 165-176
Open Access | Times Cited: 508
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Alexandra C. Walls, Brooke Fiala, Alexandra Schäfer, et al.
Cell (2020) Vol. 183, Iss. 5, pp. 1367-1382.e17
Open Access | Times Cited: 506
The origins of SARS-CoV-2: A critical review
Edward C. Holmes, Stephen A. Goldstein, Angela L. Rasmussen, et al.
Cell (2021) Vol. 184, Iss. 19, pp. 4848-4856
Open Access | Times Cited: 452
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl, Lisa E. Gralinski, Claire Johnson, et al.
Nature (2021) Vol. 591, Iss. 7850, pp. 451-457
Open Access | Times Cited: 378
The variant gambit: COVID-19’s next move
Jessica A. Plante, Brooke Mitchell, Kenneth S. Plante, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 508-515
Open Access | Times Cited: 347
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Alexandra Schäfer, Frauke Muecksch, Julio C. C. Lorenzi, et al.
The Journal of Experimental Medicine (2020) Vol. 218, Iss. 3
Open Access | Times Cited: 333
Human genetic and immunological determinants of critical COVID-19 pneumonia
Qian Zhang, Paul Bastard, Adem Karbuz, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 587-598
Open Access | Times Cited: 323
SARS-CoV-2, COVID-19 and the aging immune system
Juliet M. Bartleson, Dina Radenković, Anthony J. Covarrubias, et al.
Nature Aging (2021) Vol. 1, Iss. 9, pp. 769-782
Open Access | Times Cited: 289
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Dapeng Li, Robert J. Edwards, Kartik Manne, et al.
Cell (2021) Vol. 184, Iss. 16, pp. 4203-4219.e32
Open Access | Times Cited: 282
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
William N. Voss, Yixuan J. Hou, Nicole V. Johnson, et al.
Science (2021) Vol. 372, Iss. 6546, pp. 1108-1112
Open Access | Times Cited: 270
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19
Shea A. Lowery, Alan Sariol, Stanley Perlman
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1052-1062
Open Access | Times Cited: 263
Understanding COVID-19-associated coagulopathy
Edward M. Conway, Nigel Mackman, Ronald Q. Warren, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 10, pp. 639-649
Open Access | Times Cited: 260
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
Ryuta Uraki, Maki Kiso, Shun Iida, et al.
Nature (2022) Vol. 607, Iss. 7917, pp. 119-127
Open Access | Times Cited: 255
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
Jordan J. Feld, Christopher Kandel, Mia J. Biondi, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 5, pp. 498-510
Open Access | Times Cited: 223
Page 1 - Next Page

Scroll to top